Phase 2 Thyroid Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have given their written consent to participate
- People aged 18 years or older
- People whose general health and ability to carry out daily activities is rated at a high level (WHO Performance Status 0 or 1, meaning fully active or able to do light work)
- People with a confirmed diagnosis of anaplastic thyroid cancer (ATC), verified by a central laboratory review of tissue samples
- People whose tumor tissue has tested positive for a specific gene change called BRAF V600E or V600K mutation
- People whose cancer has not spread to distant parts of the body (no distant metastases)
- People who have either a clear airway or one that has been made safe through medical intervention
- People who are able to swallow tablets or capsules
- People who have completed full disease staging, including a PET-CT scan and CT scans of the neck, chest, and abdomen
- People who have not previously received any systemic cancer treatment, including chemotherapy, immunotherapy, or other similar therapies
- People who have not previously had radiotherapy to the area being studied
- People whose blood test results meet specific minimum levels for blood cells, liver function, kidney function, and clotting (confirm with trial site for exact values)
- People who do not have other serious or uncontrolled medical conditions
Who may not be able to join:
- People who have not given informed consent
- People who have had another cancer diagnosis within the 2 years before their ATC diagnosis (except for certain skin cancers or very early-stage cancers that have not spread)
- People whose ATC developed as a transformation from a previous type of thyroid cancer called poorly differentiated thyroid cancer
- People whose cancer has already spread to distant parts of the body
- People with underlying health conditions that, in the opinion of the investigating doctor, could make the study treatment unsafe or make it difficult to assess side effects
- People with a history of heart failure, unstable heart conditions, serious heart rhythm problems, or severe heart valve disease — these individuals would need to be assessed for the risks of undergoing general anaesthesia
- People who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ellen Kapiteijn, MD, PhD, Leiden University Medical Center
Phone: 0031-71-5263486
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
primary endpoint of the study will be R0 resection rate (efficacy).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.